Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial

Usami, Noriyasu; Yokoi, Kohei; Hasegawa, Yoshinori; Taniguchi, Hiroyuki; Shindo, Jo; Yamamoto, Masashi; Suzuki, Ritsuro; Imaizumi, Kazuyoshi; Kondo, Masashi; Shimokata, Kaoru

doi:10.1007/s10147-010-0118-x

Cited by 20 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The completion rate of four planned courses of chemotherapy in each of these two phase II trials was 95%, and the incidences of grade 3/4 neutropenia were 18% and 33%, respectively. Furthermore, the CJLSG0503 study showed that adjuvant chemotherapy with a carboplatin/gemcitabine combination regimen also had an acceptable toxicity profile . A randomized trial in 2015 that defined quality of life as the primary end‐point found that cisplatin/gemcitabine or cisplatin/docetaxel adjuvant chemotherapy for completely resected NSCLC was well tolerated .…”

Section: Discussionmentioning

confidence: 99%

“…The superiority of gemcitabine‐containing regimens in efficacy and toxicity over other regimens has been shown in several studies and it has proven to be one of the best regimens for the treatment of advanced NSCLC . Although there is limited prospective phase III clinical trial data, several phase II clinical trials have shown beneficial efficacy and reduced toxicity of cisplatin/gemcitabine as adjuvant chemotherapy . Therefore, we reviewed the charts of 100 patients to investigate the efficacy and toxicities of cisplatin/gemcitabine as adjuvant chemotherapy for patients with completely resected NSCLC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis

Wang

Hao

et al. 2017

Thoracic Cancer

View full text Add to dashboard Cite

Background: This study was conducted to evaluate the value of gemcitabine combined with cisplatin as adjuvant chemotherapy for radical resection of nonsmall cell lung cancer. Methods: Data of 100 patients who had undergone radical resection of nonsmall cell lung cancer and were treated with cisplatin/gemcitabine as adjuvant chemotherapy between June 2007 and December 2010 at the Chinese Academy of Medical Sciences were reviewed. Results: The median age was 59 years (range 36-73); 82% of the patients were male. Forty-two percent had adenocarcinoma and 55% had squamous cell carcinoma. Most patients had pathologic IIB (29%) and IIIA (44%) stage disease. Eighty-five percent of patients completed four cycles of chemotherapy, with 76% completing the planned full dose. The main reason for a reduced gemcitabine dose in 13 patients was grade 3/4 neutropenia or thrombocytopenia. The median dose and dose intensity were 8377.1 mg/m 2 and 708 mg/(m 2 /week) for gemcitabine and 293.38 mg/m 2 and 25.24 mg/(m 2 /week) for cisplatin, respectively. During follow-up the median disease-free survival was 33.8 months (95% confidence interval [CI] 15.938-51.676). Patients with squamous cell carcinoma (hazard ratio [HR] 0.404, 95% CI 0.241-0.676; P = 0.001) and pathologic stage I (HR 4.379, 95% CI 1.721-11.142; P = 0.002) achieved better disease-free survival. The survival rates at one, two, and five years were 94%, 77%, and 55%, while the survival rates without recurrence were 64%, 53%, and 39%, respectively. Conclusion: As an adjuvant chemotherapy regimen, gemcitabine with cisplatin is well tolerated. Patients with squamous cell carcinomas or pathologic stage I achieve better results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis

Wang

Hao

et al. 2017

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…Some studies revealed Chemotherapy for stage II-III non-small cell lung cancer [16][17][18] Although GEM combined with platinum has not been used in adjuvant chemotherapy for stage III NSCLC yet, data from the treatment of advanced NSCLC and several clinical trials involving stage II NSCLC with GEM have indicated that the combined treatment of GEM with platinum is more efficacious than NVB therapy in terms of safety and efficacy of postoperative chemotherapy. [19][20][21] This treatment might become a standard scheme of postoperative chemotherapy for NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Clinical Observation of Docetaxel or Gemcitabine Combined with Cisplatin in the Chemotherapy after Surgery for Stage II-III Non-small Cell Lung Cancer

Chen

Ji²,

Zhou

et al. 2015

West Indian Med J

View full text Add to dashboard Cite

Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of nonsmall cell lung cancer (NSCLC). Methods: A total of 92 patients diagnosed with NSCLC after surgery were enrolled, and they were treated with DP (DP group) and GP (GP group). The efficacy and toxicity of the medications were then compared.Results: Approximately 92.4% (85 out of 92) of the patients received chemotherapy for more than three weeks. In DP and GP groups, the incidence rates of grade III-IV thrombocytopenia were 24.4% and 6.38%, respectively, whereas the incidence rates of alopecia were 88.9% and 25.5%, respectively. The difference between the two groups was statistically significant (P < 0.05). Disease-free survival rates in DP group in one and two years were 76.5% and 50.47%, respectively, whereas in GP group were 77.8% and 49.52%, respectively. No significant difference was observed between the two groups (P > 0.05). Conclusion:These results showed similar disease-free survival rates of DP and GP therapies in one and two years after surgery for NSCLC. However, DP group exhibited higher incidence of grade III-IV thrombocytopenia and alopecia than GP group. Therefore, we should select a specific treatment for each patient according to individual differences.

show abstract

“…Less toxic chemotherapy regimens will have the advantages to maintain the quality of life of the patients and to combine them with molecular targeted drugs. The CG combination was tested in various situations of NSCLC patients such as in an adjuvant setting, for the elderly and as a second line for selected patients, showing encouraging effects [13,14,15]. In addition, an acceptable toxicity and promising median overall survival was reported in the combination of CG and bevacizumab for Non-Sq NSCLC [16].…”

Section: Discussionmentioning

confidence: 99%

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)

et al. 2011

View full text Add to dashboard Cite

Background: Gemcitabine combined with carboplatin (CG) is one of the regimens used widely for advanced non-small cell lung cancer. Improvement in its toxicity may result in good clinical outcomes. Methods: A new schedule of gemcitabine and carboplatin (CG8) was compared with the standard one (CG1). Both are 3-weekly regimens, but carboplatin is administered on day 1 in CG1 and on day 8 in CG8. Results: The response rate of CG1 was 29.2%, which was higher than that of CG8 (22.2%). Median survival times in CG1 and CG8 were 348 and 455.5 days, respectively. Grade ≧3 leukopenia, thrombocytopenia and anemia were observed in 56.0, 72.0 and 36.0% of patients with CG1 and in 33.3, 25.9 and 14.8% of patients with CG8, respectively. Whereas grade ≧3 elevation of asparatate aminotransferase, alanine aminotransferase and alkaline phosphatase was seen mainly in CG8, grade ≧3 non-hematologic toxicities such as febrile neutropenia, infection, appetite loss, diarrhea and eruption were observed only in CG1. Conclusion: CG1 is superior in response rate, but CG8 shows improved toxicities and a tendency of prolonged survival.

show abstract

Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial

Abstract: Adjuvant chemotherapy with a carboplatin and gemcitabine combination regimen has an acceptable toxicity profile, and the majority of patients completed 4 cycles of therapy.

Cited by 20 publications

References 18 publications

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis

Clinical Observation of Docetaxel or Gemcitabine Combined with Cisplatin in the Chemotherapy after Surgery for Stage II-III Non-small Cell Lung Cancer

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)

Contact Info

Product

Resources

About